Rocket Pharmaceuticals (RCKT) Competitors

Phibro Animal Health (NASDAQ:PAHC) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

Do analysts recommend PAHC or RCKT?

Phibro Animal Health presently has a consensus price target of $24.40, indicating a potential downside of 20.10%. Rocket Pharmaceuticals has a consensus price target of $18.60, indicating a potential upside of 550.35%. Given Rocket Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	2 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.83
Rocket Pharmaceuticals	1 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.41

Is PAHC or RCKT more profitable?

Phibro Animal Health has a net margin of 2.68% compared to Rocket Pharmaceuticals' net margin of 0.00%. Phibro Animal Health's return on equity of 30.51% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	2.68%	30.51%	6.89%
Rocket Pharmaceuticals	N/A	-64.92%	-56.13%

Which has higher valuation & earnings, PAHC or RCKT?

Phibro Animal Health has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.02B	1.22	$2.42M	$0.78	39.15
Rocket Pharmaceuticals	N/A	N/A	-$258.75M	-$2.63	-1.09

Which has more risk & volatility, PAHC or RCKT?

Phibro Animal Health has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.

Do institutionals and insiders have more ownership in PAHC or RCKT?

99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by insiders. Comparatively, 24.8% of Rocket Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Does the media prefer PAHC or RCKT?

In the previous week, Rocket Pharmaceuticals had 32 more articles in the media than Phibro Animal Health. MarketBeat recorded 37 mentions for Rocket Pharmaceuticals and 5 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 0.89 beat Rocket Pharmaceuticals' score of 0.20 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rocket Pharmaceuticals	1 Very Positive mention(s)	5 Positive mention(s)	29 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Phibro Animal Health beats Rocket Pharmaceuticals on 11 of the 15 factors compared between the two stocks.